Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.41 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475011 | 1.00 | MAPT (0.44) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL6475019 | 1.00 | MAPT (0.44) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL2192534 | 0.95 | KMT2A (0.47) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL2192541 | 0.95 | KMT2A (0.47) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL2192538 | 0.95 | KMT2A (0.47) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL11543256 | 0.86 | F2 (0.38) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL11543258 | 0.86 | F2 (0.38) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL6484891 | 0.86 | SMN1; SMN2 (0.49) | MAPTKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL5525558 | 0.86 | SMN1; SMN2 (0.49) | MAPTKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL5525560 | 0.86 | SMN1; SMN2 (0.49) | MAPTKMT2AMEN1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-6737438-B2 | EFFECTIVE IN MULTIDRUG RESISTANT MICE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-05-18 | — | — | US | disclosed |
| EP-1414778-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053991-A1 | Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof | COUNCIL SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-03-18 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| WO-2003011807-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053991-A1 | Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof | DHPS, TBXAS1, ABCC1 | MAPT 3696/4885KMT2A 2972/4885MEN1 4252/4885 |
| US-20030139473-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | MAPT 3939/4885KMT2A 4575/4885MEN1 4798/4885 |
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | MAPT 3845/4885KMT2A 4478/4885MEN1 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.